





Alimemazine

Area Prescribing Committee Position Statement

The prescribing of alimemazine is not supported by Barnsley Area Prescribing Committee (APC). Alimemazine has a grey non formulary classification.

- New patients requiring a sedating antihistamine should be commenced on chlorphenamine, hydroxyzine or promethazine as clinically appropriate.
- Patients currently prescribed alimemazine should have their prescription reviewed and alimemazine stopped where clinically appropriate or changed to either an alternative sedating antihistamine (chlorphenamine, hydroxyzine or promethazine), a non-sedating antihistamine or alternative treatment as appropriate.

In Barnsley, primary care expenditure on alimemazine tablets between September 2018 and August 2019 was approximately £40k.

The Medicines Management Team can support primary care prescribers in reviewing patients and deprescribing alimemazine.

Background 1,2

Alimemazine is a first-generation (sedating) antihistamine, alongside chlorphenamine, hydroxyzine and promethazine. Alimemazine is licensed for the treatment of urticaria and pruritis in children over 2 years and adults. It is also licensed in pre-medication as a sedative prior to general anaesthesia in children aged 2 to 7 years. It may be used 'off license' for other indications e.g. allergic rhinitis, insomnia in children and sedation prior to CT/MRI imaging scans in paediatric patients. There are a range of sedating and non-sedating antihistamines that are significantly more cost effective than alimemazine. There is little clinical evidence to suggest that alimemazine is superior to other marketed antihistamine preparations and patients can vary widely in their response.

Rationale for switching from alimemazine to an alternative antihistamine / alternative treatment 1.2.3.4.5.6.7.8.

- There is **no robust clinical evidence** that alimemazine is more effective than either chlorphenamine, hydroxyzine, promethazine or any of the non-sedating antihistamines.
- NICE Clinical Knowledge Summary for urticaria advises that in patients with mild urticaria due to a known avoidable cause then the condition is likely to be self-limiting without treatment. Patients with symptoms requiring treatment should be prescribed a non-sedating antihistamine for up to 6 weeks.
- NICE Clinical Knowledge Summary for patients with allergic rhinitis advises self-management e.g. provide advice on allergen avoidance techniques and drug treatment options.

If the person has mild-to-moderate intermittent or mild persistent allergic rhinitis symptoms:

- o Advise on the 'as-needed' use of an intranasal antihistamine first-line, or a second-generation, non-sedating oral antihistamine, depending on the person's age and personal preference.
 - Advise that intranasal antihistamines (azelastine) have a faster onset of action and are more effective than oral preparations.
 - Oral antihistamine options include loratadine or cetirizine, which may be available overthe-counter.

Consult the CKS for information on drug treatment for moderate to severe persistent symptoms, or where initial drug treatment is ineffective. Barnsley allergic rhinitis guidance available at: https://best.barnsleyccq.nhs.uk/clinical-support/medicines/prescribing-guidelines/Allergic%20Rhinitis%20Guidelines.pdf

- NICE guidance on clinical sedation (<u>CG 112</u>) advises using chloral hydrate (for children under 15kg) and midazolam for under 19s who are unable to tolerate painless procedures such as diagnostic imaging.
- Sedating antihistamines should not be used long term unless clinically indicated.

Deprescribing 1,3,4,9

Patients who are under the care of a specialist, should be reviewed in liaison with the specialist and alternative treatment options discussed.

- Discuss alternative treatment options suitable for the patient's current condition.
- This may involve self-care with an over the counter treatment option if the patient is taking alimemazine for mild to moderate hay fever. Mild to moderate hay fever/seasonal rhinitis is included within the NHS England guidance on conditions for which over the counter items should not routinely be prescribed in primary care. NHS Barnsley CCG Self-Care guidance can be found at: https://best.barnsleyccg.nhs.uk/clinical-support/medicines/prescribing-guidelines/Self_Care_Guidance.pdf
 Please note the general exceptions to the guidance on page 2.
- For other indications consider a **switch** from alimemazine to either an alternative sedating antihistamine (chlorphenamine, hydroxyzine or promethazine), a non-sedating antihistamine or alternative treatment as appropriate. Refer to Appendix 1 for licensed indications and dosages for other anti-histamines.
- Hydroxyzine is contraindicated in patients with a prolonged QT interval, Torsade de Pointes and patients who have risk factors for QT interval prolongation. (See the hydroxyzine SmPC³ for further information). The MHRA recommends that the maximum adult daily dose of hydroxyzine is 100mg. Promethazine is contraindicated for use in children less than two years of age because of the potential for fatal respiratory depression.
- Chlorphenamine, hydroxyzine, promethazine and the non-sedating antihistamines; cetirizine, fexofenadine and loratadine, have a green classification on the Barnsley Formulary.
- Alternatively consider non-drug treatments.
- If a patient is unable to stop alimemazine, refer them to a specialist for a review. Note that it is more cost effective to prescribe the liquid formulation of alimemazine as Alfresed® syrup (see costs below).

Costs ¹⁰
Antihistamine cost comparison (Drug Tariff May 2022 and NHS dm+d browser)

Product	Dose in adults ² (Refer to BNF and SPC for full dosage information, including for elderly patients)	Cost per 28 days treatment
Alimemazine Tartrate tablets 10mg	10mg 2-3 times daily	£225.76 - £338.64 (£112.88 for 28 tablets)
Alfresed® 30mg/5ml syrup	10mg 2-3 times daily	£92.07 - £138.60 (£99 for 100ml)
Alimemazine 30mg/5ml oral Solution sugar free	10mg 2-3 times daily	£158.72- £238.93 (£170.67 for 100ml)
Alimemazine 30mg/5ml oral Solution	10mg 2-3 times daily	£226.46 - £340.91 (£243.51 for 100ml)
Alfresed® 7.5mg/5ml syrup	10mg 2-3 times daily	£331.97 - £498.40 (£89 for 100ml)
Alimemazine 7.5mg/5ml oral solution sugar free	10mg 2-3 times daily	£469.46 - £704.82 (£125.86 for 100ml)
Alimemazine 7.5mg/5ml oral solution	10mg 2-3 times daily	£669.83- £1005.65 (179.58 for 100ml)
Chlorphenamine 4mg tablets	4mg every 4-6hrs (max 24mg in 24hrs)	£12.28 (based on every 6 hours, £3.07 for 28 tablets)

Chlorphenamine 2mg/5ml oral solution		£20.76 (based on every 6 hours, £2.78 for 150ml)
Hydroxyzine 25mg tablets	25 mg up to 3-4 times daily	£3.39 - £4.52 (£1.13 for 28 tablets)
Promethazine 10mg tablets	10-20mg 2-3 times daily	£4.16 - £12.48 (£4.16 for 56 tablets)
Promethazine 5mg/5ml oral solution sugar free	10-20mg 2-3 times daily	£15.96 - £47.88 (£2.85 for 100ml)
Cetirizine 10mg tablets	10mg daily	£0.74 (£0.79 for 30 tablets)
Cetirizine 1mg/ml oral solution sugar free		£23.74 (£16.96 for 200ml)
Loratadine 10mg tablets	10mg daily	£0.80 (£0.86 for 30 tablets)_
Loratadine 5mg/5ml oral solution		£13.69 (£4.89 for 100ml)

References

- 1. SmPC Alimemazine https://www.medicines.org.uk/emc/product/6649/smpc <Accessed 28.01.20>
- 2. BNF chapter 3 allergic conditions https://bnf.nice.org.uk/treatment-summary/antihistamines-allergen-immunotherapy-and-allergic-emergencies.html https://bnf.nice.org.uk/treatment-summary/antihistamines-allergen-immunotherapy-and-allergic-emergencies.html https://bnf.nice.org.uk/treatment-summary/antihistamines-allergen-immunotherapy-and-allergic-emergencies.html https://bnf.nice.org.uk/treatment-summary/antihistamines-allergen-immunotherapy-and-allergic-emergencies.html https://bnf.nice.org.uk/treatment-summary/antihistamines-allergen-immunotherapy-and-allergic-emergencies.html <a href="https://bnf.nice.org.uk/treatment-summary/antihistamines-allergen-immunotherapy-and-allergen-immunotherapy-allergen-immunotherapy-and-allergen-immunotherapy-allergen-immunotherapy-and-allergen-immunotherapy-and-allergen-immunotherapy-an
- 3. SmPC Hydroxyzine https://mhraproducts4853.blob.core.windows.net/docs/1ab359c0ef0c0846f5e5dc94750137ac98052abf https://mhraproducts4853.blob.core.windows.net/docs/1ab359c0ef0c0846f5e5dc94750137ac98052abf https://mhraproducts4853.blob.core.windows.net/docs/1ab359c0ef0c0846f5e5dc94750137ac98052abf
- 4. SmPC Chlorphenamine https://www.medicines.org.uk/emc/product/20/smpc < Accessed 21.04.20>
- 5. SmPC Promethazine 25mg tablets https://www.medicines.org.uk/emc/product/5588/smpc and SMPC Promethazine 5mg/5ml oral solution https://www.medicines.org.uk/emc/product/5586/smpc <a href="https://www.medicines.org.uk/emc/product/smpc-acces.org.uk/emc/product/smpc-acces.org.uk/emc/product/sm
- 6. NICE Clinical Knowledge Summaries Urticaria https://cks.nice.org.uk/urticaria#!scenario Accessed <28.01.20>
- 7. NICE Clinical Knowledge Summaries Allergic Rhinitis https://cks.nice.org.uk/allergic-rhinitis#!scenario . Accessed <28.01.20>
- 8. NICE CG112 guidance on Sedation in under 19s https://www.nice.org.uk/guidance/cg112 <Accessed 28.01.20>
- 9. MHRA safety alert https://www.gov.uk/drug-safety-update/hydroxyzine-atarax-ucerax-risk-of-qt-interval-prolongation-and-torsade-de-pointes https://www.gov.uk/drug-safety-update/hydroxyzine-atarax-ucerax-risk-of-qt-interval-prolongation-and-torsade-de-pointes https://www.gov.uk/drug-safety-update/hydroxyzine-atarax-ucerax-risk-of-qt-interval-prolongation-and-torsade-de-pointes https://www.gov.uk/drug-safety-update/hydroxyzine-atarax-ucerax-risk-of-qt-interval-prolongation-and-torsade-de-pointes https://www.gov.uk/drug-safety-update/hydroxyzine-atarax-ucerax-risk-of-qt-interval-prolongation-and-torsade-de-pointes <a href="https://www.gov.uk/drug-safety-update/hydroxyzine-atarax-ucerax-risk-of-qt-interval-prolongation-atarax-ucerax-risk-of-qt-interval-prolongation-atarax-ucerax-risk-of-qt-interval-prolongation-atarax-ucerax-risk-of-qt-interval-prolongation-atarax-ucerax-risk-of-qt-interval-prolongation-atarax-ucerax-risk-of-qt-interval-prolongation-atarax-ucerax-risk-of-qt-interval-prolongation-atarax-ucerax-risk-of-qt-interval-prolongation-atarax-ucerax-risk-of-qt-interval-prolongation-atarax-ucerax-risk-of-qt-interval-prolongation-atarax-ucerax-risk-of-qt-interval-prolongation-atarax-ucerax-risk-of-qt-interval-prolongation-atarax-ucerax-risk-of-qt-interval-prolongation-atarax-ucerax-risk-of-qt-interval-prolongation-atarax-ucerax-risk-of-qt-interval-prol
- 10. Drug Tariff Online https://www.nhsbsa.nhs.uk/pharmacies-gp-practices-and-appliance-contractors/drug-tariff https://www.nhsbsa.nhs.uk
- 11. BNFc chapter 3 allergic conditions https://bnfc.nice.org.uk/treatment-summary/antihistamines-allergen-immunotherapy-and-allergic-emergencies.html https://bnfc.nice.org.uk/treatment-summary/antihistamines-allergen-immunotherapy-and-allergic-emergencies.html https://bnfc.nice.org.uk/treatment-summary/antihistamines-allergen-immunotherapy-and-allergic-emergencies.html https://bnfc.nice.org.uk/treatment-summary/antihistamines-allergen-immunotherapy-and-allergic-emergencies.html https://bnfc.nice.org.uk/treatment-summary/antihistamines-allergen-immunotherapy-and-allergen-immunothera
- 12. SmPC Alimemazine syrup 7.5mg/5ml https://www.medicines.org.uk/emc/product/415/smpc <Accessed May 2020>

Development Process

This position statement was ratified at the Area Prescribing Committee on 8th July 2020 (minor amendment June 2022: addition of Alfresed® syrup).

<u>Appendix 1 – Indications and dosages for antihistamines (Common indications only. For further information regarding indications and current dosages please see SmPC for a particular product or the BNF/BNFc).</u>

Urticaria⁶

NICE advises that for people with mild urticaria with an identifiable and avoidable cause/trigger, advise that urticarial is likely to be self-limiting without treatment. For people with symptoms requiring treatment, offer a non-sedating anthistamine (for example cetirizine, loratidine or fexofenadine) for up to 6 weeks (use clinical judgement to determine the duration of treatment).

https://cks.nice.org.uk/urticaria#!scenario

Drug	Adult ² doses (over <u>12</u> <u>years</u>) Please check SmPC or BNF for elderly patients	Paediatric doses ^{11,12}
Non-sedating Anti-histamines		
Cetirizine	1 tablet (10 mg) once daily	Children aged 1 to 23mths: 250micrograms/kg twice daily (unlicensed use)
		Children aged 2 to 5 years: 2.5 mg twice daily (2.5ml oral solution twice daily)
		Children aged 6 to 11years: 5mg twice daily (5 ml oral solution twice daily)
		Cetirizine is available as a 5mg/5ml oral solution
Loratadine	1 tablet (10 mg) once daily	Children aged 2 to 12 years of age are dosed by weight:
		Body weight 30kg or less: 5ml (5mg) of the syrup once daily
		Body weight more than 30kg: 10ml (10mg) of the syrup once daily
		Loratadine is available as a 5mg/5ml oral solution
<u>Sedating Anti-histamines</u>		
Alimemazine	10mg 2-3 times daily Max 100mg per day	Children aged 0 to 1yrs: contraindicated for use in children less than 2 years of age due to the risk of marked sedation and respiratory depression
		Children aged 2 to 4 years: 2.5mg three or four times daily
		Children aged 5 to 11years: 5mg three or four times daily.
		Alimemazine is available as a 7.5mg/5ml oral solution (it is

		more cost effective to prescribe as Alfresed® syrup)
Chlorphenamine	1 tablet (4mg) every 4 to 6 hourly. Maximum daily dose: 6 tablets (24 mg) in any 24 hours	Children aged 1 to 23mths: 1mg (2.5ml) twice daily. The minimum interval between the doses should be 4 hours. Maximum daily dose 2mg (5ml) in any 24 hours
		Children aged 2 to 5 years: 1mg (2.5ml) every 4 to 6 hourly. Maximum daily dose: 6mg (15ml) in any 24 hours
		Children aged 6 to 11 years: 2mg (5ml) every 4 to 6 hourly. Maximum daily dose: 12mg (30ml)) in any 24 hours
		Chlorphenamine is available as a 2mg/5ml oral solution
Hydroxyzine	Unlicensed for use in Urticaria	Unlicensed for use in Urticaria
Promethazine	5mg/5ml oral solution: 10-20mg 2-3 times daily 25mg tablets: 25 mg as a single dose. Increasing to a maximum of 25 mg bd as required	Children 0 to 2 years Contraindicated for use in Children under 2years because of the potential for fatal respiratory depression Children 2 to 5 years Either 5–15mg as a single dose Or 5 mg bd Maximum daily dose 15 mg Children 5 to 10 years 25 mg as a single dose* Maximum daily dose 25 mg. Children over 10 years 25 mg as a single dose* Increasing to a maximum of 25 mg bd as required Promethazine is available as a 5mg/5ml oral solution

^{*}Single doses are best taken at night

Allergic Rhinitis⁷ (Hayfever)

NICE advise the use of self-management strategies followed by 'as-needed' use of an intranasal antihistamine first-line, or a second-generation, non-sedating oral antihistamine, depending on the person's age and personal preference.

https://cks.nice.org.uk/allergic-rhinitis#!scenario

https://cks.nice.org.uk/allergic-rhinitis#!scen		Donalistria dona
Drug	Adult Dose (over 12yrs). Please check SmPC for	Paediatric dose
	elderly patients	
Non-sedating Anti-histamines	orderly patronne	
Cetirizine	10 mg once daily	Seasonal allergic rhinitis Children aged 2 to 5 years: 2.5 mg twice daily (2.5 ml twice daily)
		Seasonal allergic rhinitis and perennial rhinitis Children aged 6 to 11 years: 5 mg twice daily (5 ml oral solution twice daily)
		Cetirizine is available as a 5mg/5ml oral solution
Loratadine	1 tablet (10 mg) once daily	Children aged 2 to 12 years of age are dosed by weight:
		Body weight 30kg or less: 5ml (5mg) of the syrup once daily
		Body weight more than 30kg: 10ml (10mg) of the syrup once daily
		Loratadine is available as a 5mg/5ml oral solution
Sedating Anti-histamines		
Alimemazine	Unlicensed for use in allergic rhinitis	Unlicensed for use in allergic rhinitis
Chlorphenamine	1 tablet (4mg) every 4 to 6 hourly. Maximum daily dose: 6 tablets (24 mg) in	Children aged 1 to 23mths: 250micrograms/kg twice daily (unlicensed use)
	any 24 hours	Children aged 1 to 23mths: 1mg (2.5ml) twice daily. The minimum interval between the doses should be 4 hours. Maximum daily dose:2mg (5ml) in any 24 hours
		Children aged 2 to 5 years: 1mg (2.5ml) every 4 to 6 hourly. Maximum daily dose: 6mg (15ml) in any 24 hours
		Children aged 6 to 11 years: 2mg (5ml) every 4 to 6 hourly. Maximum daily dose: 12mg (30ml)) in any 24 hours
		Chlorphenamine is available as a 2mg/5ml oral solution

Hydroxyzine	Unlicensed for use in allergic rhinitis	Unlicensed for use in allergic rhinitis
Promethazine	25 mg as a single dose. Increasing to a maximum of 25 mg twice daily as required	Children 0 to 2 years: Contraindicated for use in Children under 2years because of the potential for fatal respiratory depression
		Children 2 to 4 years: 5mg twice daily OR 5–15 mg as a single dose preferably at night. Or 5 mg bd. Maximum daily dose 15 mg
		Children 5 to 9 years: 5-10mg twice daily OR 10-25mg as a single dose*. Maximum daily dose 25 mg
		Children 10 years and over: 10-20mg 2-3times daily OR 25 mg as a single dose* (Increased to a maximum of 25 mg twice daily as required)
		Promethazine is available as a 5mg/5ml oral solution

^{*}Single doses are best taken at night

Sedation⁸- including sedation for diagnostic and therapeutic conditions

https://www.nice.org.uk/guidance/cg112

https://www.nice.org.uk/guidance/cg112	T	T =
Drug	Adult Dose (over 12yrs). Please check SmPC for elderly patients	Paediatric dose
Sedating Anti-histamines		
Alimemazine (premedication to aneasthesia)	Unlicensed for use in adult sedation	Children 0 to 23mths: contraindicated for use in children less than 2 years of age due to the risk of marked sedation and respiratory depression. Children 2 to 3 years: 2 mg per kg bodyweight 1 – 2 hours before the operation.(Unlicensed use)
		Children 3 to 6 years: 2 mg per kg bodyweight 1 – 2 hours before the operation Alimemazine is available as a 7.5mg/5ml oral solution. For higher doses to reduce ethanol exposure the higher strength Alimemazine 30mg/5ml oral solution may
		be used. (It is more cost

Chlorphenamine Unlicensed for use in adult sedation Hydroxyzine Unlicensed for use in adult sedation Unlicensed for use in adult sedation Promethazine 25 or 50 mg as a single night time dose. Children 0 to 2 years: Contraindicated for use in Children under 2years because of the potential for fatal respiratory depression. Children 2 to 5 years: 15 or 20 mg as a single night time dose Children 5 to 10 years: 20 or 25 mg as a single night time dose. Children over 10 years and adults: 25 or 50 mg as a single night time dose			effective to prescribe alimemazine liquid formulation as Alfresed® syrup)
Promethazine 25 or 50 mg as a single night time dose. Children 0 to 2 years: Contraindicated for use in Children under 2years because of the potential for fatal respiratory depression. Children 2 to 5 years: 15 or 20 mg as a single night time dose Children 5 to 10 years: 20 or 25 mg as a single night time dose. Children over 10 years and adults: 25 or 50 mg as a single night	Chlorphenamine		
night time dose. Contraindicated for use in Children under 2years because of the potential for fatal respiratory depression. Children 2 to 5 years: 15 or 20 mg as a single night time dose Children 5 to 10 years: 20 or 25 mg as a single night time dose. Children over 10 years and adults: 25 or 50 mg as a single night	Hydroxyzine		
Promethazine is available as	Promethazine	25 or 50 mg as a single	Children 0 to 2 years: Contraindicated for use in Children under 2years because of the potential for fatal respiratory depression. Children 2 to 5 years: 15 or 20 mg as a single night time dose Children 5 to 10 years: 20 or 25 mg as a single night time dose. Children over 10 years and adults: 25 or 50 mg as a single night time dose

^{*}Single doses are best taken at night